Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.753.136 €): Klinische Entwicklung von oralem Oleylphosphocholin als neues Medikament zur Behandlung der Kutanen Leishmaniose der Alten Welt Hor01.05.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Klinische Entwicklung von oralem Oleylphosphocholin als neues Medikament zur Behandlung der Kutanen Leishmaniose der Alten Welt
Cutaneous leishmaniasis (CL) is a poverty related, neglected tropical disease, which is without an effective and cheap systemic treatment. The aim of TT4CL is to develop a new orally available drug for treatment of CL aimed towards registration with stringent regulatory authorities. Oleylphosphocholine (OlPC), regarded as a new drug by the FDA, is structurally related to the anti-leishmanial miltefosine. It is being developed as an immediate-release tablet for the treatment of CL and, currently, is the only systemically delivered drug specifically being developed for this indication. OlPC is active in vitro and in vivo against different CL-causing Leishmania parasite species and shows curative advantage over miltefosine in rodent models of leishmaniasis. The primary objective of this study is to complete the pre-clinical package that is essential for the subsequent clinical development of OlPC. The project will aim to optimize the synthesis and formulation of OlPC, including stability testing that is appropriate for tropical climates. It will include in vitro drug sensitivity analyses in parasites causing CL (Leishmania tropica and L. major) in the Islamic Republic of Iran, with our endemic-country partner. Comparative studies in animal models with existing anti-leishmanial compounds will establish efficacy advantages and determine pharmacokinetic-pharmacodynamic relationships for OlPC. Phase 1 studies will confirm tolerability and pharmacokinetics of single doses and multiple dosing regimens. Results will be used to guide decisions by future partners on the clinical development of OlPC. This proposal directly addresses the priorities highlighted in this H2020 call. To our knowledge, we are the only consortium that is implementing this type of approach, and there is no other interest in the pharmaceutical sector to carry out a development programme for the oral treatment of CL.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| AVIVIA BEHEER B.V. | 591.000 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 710.150 € |
| London School of Hygiene and Tropical Medicine Royal Charter | 355.568 € |
| Oblita Therapeutics | 367.550 € |
| St George's Hospital Medical School | 1.178.864 € |
| Tehran University OF Medical Sciences | 371.376 € |
| Universitaetsklinikum Tuebingen | 0,00 € |
| University of York | 178.628 € |
Quelle: https://cordis.europa.eu/project/id/815622
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "AVIVIA BEHEER B.V. - EU-Förderung (3.753.136 €): Klinische Entwicklung von oralem Oleylphosphocholin als neues Medikament zur Behandlung der Kutanen Leishmaniose der Alten Welt"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
